EUVIMEDEUVIMED entdecken
Pragmatische StudieRandomisierte kontrollierte Studie

Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial

Nimish N Shah iD, Lama Ghazi iD, Yu Yamamoto iD, Sanchit Kumar iD, Melissa Martin, Michael Simonov, Ralph J Riello Iii iD, Kamil F Faridi iD, Tariq Ahmad iD, F Perry Wilson iD, Nihar R Desai

Circulation: Cardiovascular Quality and Outcomes · 2024-05 · 17 (5)

DOI: 10.1161/circoutcomes.123.010335 ↗

Kurz gefasst

Pragmatische Studie in der Zeitschrift Circulation: Cardiovascular Quality and Outcomes, 2024-05. Verfasst von Nimish N Shah und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (N.N.S., K.F.F., T.A., F.P.W., N.R.D.). Hauptthemen laut MEDLINE: Biomarkers, Cholesterol, LDL, Electronic Health Records, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lipid-lowering therapy (LLT) is underutilized for very high-risk atherosclerotic cardiovascular disease. PROMPT-LIPID (PRagmatic Trial of Messaging to Providers about Treatment of HyperLIPIDemia) sought to determine whether electronic health record (EHR) alerts improve 90-day LLT intensification in patients with very high-risk atherosclerotic cardiovascular disease. METHODS: PROMPT-LIPID was a pragmatic trial in which cardiovascular and internal medicine clinicians within Yale New Haven Health (New Haven, CT) were cluster-randomized to receive an EHR alert with individualized LLT recommendations or no alert for outpatients with very high-risk atherosclerotic cardiovascular disease and LDL-C (low-density lipoprotein cholesterol), ≥70 mg/dL. The primary outcome was 90-day LLT intensification (change to high-intensity statin and addition of ezetimibe or PCSK9i [proprotein subtilisin/kexin type 9 inhibitors]). Secondary outcomes included LDL-C level, proportion of patients with LDL-C of 2-fold increase in LLT intensification. EHR alerts, coupled with strategies to reduce clinician dismissal, may help address persistent gaps in LDL-C management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04394715, https://www.clinicaltrials.gov/ct2/show/study/NCT04394715

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersCholesterol, LDLElectronic Health RecordsHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasPCSK9 InhibitorsAgedFemaleHumansMaleMiddle AgedAnticholesteremic AgentsClinical Decision-MakingDrug Therapy, CombinationEzetimibeHeart Disease Risk FactorsPractice Patterns, Physicians'Proprotein Convertase 9Risk AssessmentTime FactorsTreatment Outcome

Stichwörter der Autor:innen

atherosclerosiscardiovascular diseasecholesterol-LDLelectronic health record

Substanzen

Anticholesteremic AgentsBiomarkersCholesterol, LDLEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (N.N.S., K.F.F., T.A., F.P.W., N.R.D.).
  • Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, AL (L.G.).
  • Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, CT (Y.Y., S.K., M.M., M.S., R.J.R., T.A., F.P.W., N.R.D.).

ORCID-Profile: Nimish N Shah, Lama Ghazi, Yu Yamamoto, Sanchit Kumar, Ralph J Riello Iii, Kamil F Faridi, Tariq Ahmad, F Perry Wilson

Zitieren

APA

Shah, N. N., Ghazi, L., Yamamoto, Y., Kumar, S., Martin, M., Simonov, M., Riello Iii, R. J., Faridi, K. F., Ahmad, T., Wilson, F. P., & Desai, N. R. (2024). Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial. Circulation: Cardiovascular Quality and Outcomes, 17(5). https://doi.org/10.1161/circoutcomes.123.010335

Vancouver

Shah NN, Ghazi L, Yamamoto Y, Kumar S, Martin M, Simonov M, et al. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial. Circulation: Cardiovascular Quality and Outcomes. 2024;17(5). doi:10.1161/circoutcomes.123.010335

BibTeX
@article{Shah2024,
  author = {Shah, Nimish N and Ghazi, Lama and Yamamoto, Yu and Kumar, Sanchit and Martin, Melissa and Simonov, Michael and Riello Iii, Ralph J and Faridi, Kamil F and Ahmad, Tariq and Wilson, F Perry and Desai, Nihar R},
  title = {Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial},
  journal = {Circulation: Cardiovascular Quality and Outcomes},
  year = {2024},
  volume = {17},
  number = {5},
  doi = {10.1161/circoutcomes.123.010335}
}
Kostenlos starten →